Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks
PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.
You may also be interested in...
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
Roche, through Genentech, returns to the PhRMA fold after leaving the trade group in 2009; Gilead is a first-time member; both are retaining their BIO memberships as well.
The pharmaceutical industry fared pretty well in the tumultuous first year of President Trump. But will the industry be able to stay united on key issues in 2018 – or succumb to the divisiveness of the era?